Ariana Pelosci

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.

Nicole Lamanna, MD, discusses addressing a clinically unmet need among patients with CLL who have relapsed on multiple prior lines of therapy.

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.

Updated OS findings from the PERLA trial showed continued success with dostarlimab plus chemotherapy in patients with advanced non–small cell lung cancer.

Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.

The FDA has pushed back PDUFA dates for sotorasib and obeticholic acid for metastatic CRC and primary biliary cholangitis indications.

Adolescents and young adults with cancer more commonly experience financial toxicity and unmet social needs.

Those with pathogenic variants had a higher likelihood of communicating with clinicians and family members about test results.

Review data demonstrated a variation in opioid prescriptions for cancer-related pain between oncology providers and pain management providers.

Regardless of type 2 diabetes status, pancreatic cancer risk was reduced with metabolic-bariatric surgery for patients who were obese.

TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

Results from KEYNOTE-671 show an improvement in OS when a neoadjuvant/adjuvant regimen of pembrolizumab was used to treat patients with NSCLC.

Results from the INNATE trial showed the use of sotigalimab to be a safe and efficacious regimen for patients with rectal cancer.

Findings from the phase 3 CheckMate 77T trial support the approval of nivolumab plus chemotherapy for resectable NSCLC.

Efficacy findings were enhanced when 177Lu-Dotatate was used to treat patients with grade II/III recurrent meningioma.

Hypofractionated postmastectomy radiotherapy was noninferior to standard radiation in patients who underwent a mastectomy.

Results from the ARANOTE trial support the supplemental new drug application for darolutamide/ADT in metastatic hormone-sensitive prostate cancer.

A subgroup analysis from the PERSEUS trial showed sustained PFS benefit in patients with newly diagnosed multiple myeloma receiving D-VRd.

Findings from the phase 3 IMROZ trial support the FDA approval of the combination therapy for newly diagnosed not eligible for ASCT multiple myeloma.

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.

Results from the MARIPOSA-2 trial led to the approval of amivantamab plus chemotherapy in patients with EGFR-mutated NSCLC.

Results from the NATALEE trial of ribociclib/NSAI vs NSAI alone support the approval for patients with HR-positive, HER2-negative early breast cancer.

NO-CUT trial data show that DRFS was maintained when non-operative management was used in patients with pMMR locally advanced rectal cancer.

Follow-up data show breastfeeding to be feasible among patients with hormone receptor–positive breast cancer during an endocrine therapy break.

Patients with NSCLC across various subgroups did not see a disease-free survival benefit with adjuvant durvalumab compared with placebo.

Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA.

Patients with EGFR-mutated NSCLC had sustained HRQOL when treated with amivantamab plus lazertinib vs osimertinib.